Medical savings accounts: Assessing their impact on efficiency, equity, and financial protection in health care

Olivier J. Wouters,1 Jonathan Cylus,1,2 Wei Yang,1,3 Sarah Thomson,1,2,4 Martin McKee2,5

1 LSE Health, London School of Economics and Political Science, London, UK
2 European Observatory on Health Systems and Policies, London, UK
3 Centre for Health Services Studies, University of Kent, Kent, UK
4 WHO Barcelona Office for Health Systems Strengthening, Barcelona, Spain
5 London School of Hygiene and Tropical Medicine, London, UK

ABSTRACT

Medical savings accounts (MSAs) allow enrollees to withdraw money from earmarked funds to pay for health care. The accounts are usually accompanied by out-of-pocket payments and a high-deductible insurance plan. This article reviews the association of MSAs with efficiency, equity, and financial protection. We draw on evidence from four countries where MSAs play a significant role in the financing of health care: China, Singapore, South Africa, and the United States of America. The available evidence suggests that MSA schemes have generally been inefficient and inequitable and have not provided adequate financial protection. The impact of these schemes on long-term health-care costs is unclear. Policymakers and others proposing the expansion of MSAs should make explicit what they seek to achieve given the shortcomings of the accounts.
Introduction

A number of countries are considering whether medical savings accounts (MSAs) are a viable way of financing health care. This is in large part due to Singapore’s apparent success in using these accounts in combination with other financing mechanisms to provide high-quality care at comparatively low cost. In recent years, MSAs have been discussed by policy makers and interest groups in Canada and some European countries, although they have not been introduced in any of these nations (Herley et al. 2008; Thomson et al. 2010).

One reason for this interest is that MSAs have been promoted by prominent think tanks. For example, the Adam Smith Institute in the United Kingdom (UK) has called for a rapid move away from the National Health Service — a universal, tax-funded health system — to a system funded through individual MSAs (Worstall 2013; Goldsworthy 2014). Although the argument was based on questionable cross-country comparisons and was light on detail of how such a scheme would work, the recommendation should not be ignored as the Institute is influential with the government that came to power in the 2015 general election in the UK. In the United States of America (USA), a widely-circulated book published by the Brookings Institution lauded the Singaporean health system for providing “affordable excellence” (Haseltine 2013), although this interpretation was subsequently challenged (McKee and Busse 2013). There are current Republican proposals to repeal the Patient Protection and Affordable Care Act, colloquially known as Obamacare, and to expand the use of MSAs in the USA (Lueck 2015; Park and Biniek 2015).

MSAs allow individuals and/or households to withdraw money from earmarked funds to pay for eligible health-care costs; employers often also contribute to these personalised accounts. Enrolees therefore pool risks over time, although they do not pool risks across the wider population. The accounts are usually accompanied by out-of-pocket payments and a high-deductible insurance plan that covers catastrophic costs. In the USA, this combination is often called ‘consumer-directed health care’ (Buchmueller 2008). MSA plans can differ in terms of cost sharing (i.e. user charges), contribution, and spending rules.

The key aims of MSAs include: (1) encouraging personal responsibility for health and health care; (2) increasing provider choice for patients; (3) enhancing financial protection; (4) improving efficiency; and (5) controlling health-care costs. The extent to which they achieve these goals is widely debated (Gramm 1994; Massaro and Wong 1995; Pauly and Goodman 1995; Thorpe 1995; Hsiao 1995; Dixon 2002; Davis 2004; Lee and Zapert 2005; McConnell 2005; Robinson 2005; Bloche 2006, 2007; Buntin et al. 2006; Remler and Glied 2006; Baicker, Dow and Wolfson 2007; Woolhandler and Himmelstein 2007; Haseltine 2013; McKee and Busse 2013; Park 2015).

This article provides a critical assessment of MSAs as a financing option for health care. We briefly outline the key features of existing MSA schemes, and review the evidence on the association of MSAs with efficiency, equity, and financial protection.

MSA designs

MSAs currently only play a significant role in the financing of health care in China, Singapore, South Africa, and the USA (Table 1). In Singapore, Medisave is a compulsory
MSA scheme launched in 1984 to limit government exposure to health-care costs. It is complemented by two other components: MediShield, a voluntary high-deductible, catastrophic insurance plan, and the Medical Endowment Fund (Medifund), a safety net for poorer people. Medisave and Medishield are part of the Central Provident Fund, a government-managed savings scheme (Barr 2001; Hsiao 2001; Asher and Nandy 2006; Asher, Ramesh, and Maresso 2008). In recent years, other components aimed at high-income individuals, older people, and long-term care recipients have been introduced.

China introduced compulsory MSAs for all urban employees in 1998 to try to increase the proportion of insured individuals, protect patients from impoverishment due to medical expenses, and enhance price competition in primary care to contain costs. The accounts are accompanied by a social risk-pooling fund that covers catastrophic medical expenses. In 2003, the government also introduced a government-managed, voluntary financing scheme for the rural Chinese population, and many counties now use a combination of MSAs and high-deductible catastrophic insurance to cover this population (Yip and Hsiao 1997; Lei and Lin 2009; Yip and Hsiao 2009). The administration of the rural scheme has been devolved to local governments.

In South Africa, voluntary MSAs were introduced in 1994 to limit financial risk for private insurers. Initially, insurers were allowed to design their own MSA plans. During the 2000s, regulation of MSAs was phased in to deter aggressive selection of healthy individuals, to minimise the exploitation of tax loopholes, and to reduce the threat to social solidarity (McLeod and McIntyre 2008).

MSAs were introduced in the USA in 2003 and are generally known as health savings accounts (HSAs). HSAs are voluntary, employer-sponsored schemes that are often managed by private insurers or other financial institutions; they are also available for individual purchase. The aim of HSAs is to increase insurance coverage rates and to curb health expenditure growth. Between 2006 and 2010, the number of registered HSAs grew from 1.3 million to 8.4 million, corresponding to an increase from USD 873.4 million to USD 12.4 billion in HSA assets (Fronstin 2012). Individuals still have to pay for some health-care costs out-of-pocket, and there is no government-underwritten catastrophic coverage (Glied 2008). Health reimbursement accounts (HRAs) — another common type of consumer-directed health plan — were available prior to 2003. HRAs operate similarly to HSAs, but the former are not portable between employers and only employers can contribute to them. There is also no limit on how much employers can contribute each year to HRAs, and it is not required that the accounts be coupled with high-deductible insurance plans (Buchmueller 2008).

Table 1. Key features of MSA schemes

<table>
<thead>
<tr>
<th>Programme</th>
<th>Singapore</th>
<th>China</th>
<th>South Africa</th>
<th>USA*</th>
</tr>
</thead>
<tbody>
<tr>
<td>National government scheme (MediSave) accompanied by a voluntary, high-deductible insurance plan to cover catastrophic expenditure</td>
<td>National government policy for urban employee insurance participants with regional variation in design. Other schemes (e.g., for rural populations)</td>
<td>Operates in private insurance market; minimal national regulation</td>
<td>Operates in private insurance market within a national regulatory framework; scheme design varies across insurance plans</td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>Compulsory; employees and employers pay a % of employee wages (varies by age); government tops up accounts on an ad hoc basis; annual contribution cap</td>
<td>Compulsory for urban employees, with employees and employers paying a % of employee wages; the government also contributes in some regions; the contributions vary across regions for other schemes (e.g., for rural population)</td>
<td>Voluntary; annual contribution cap; employees and employers contribute</td>
<td>Voluntary; annual contribution cap; employees and employers contribute</td>
</tr>
<tr>
<td>Incentives to save</td>
<td>Contributions are tax-exempt, accumulate interest, and can be bequeathed</td>
<td>Saving is compulsory; contributions, interest, and withdrawals are not taxed</td>
<td>Contributions, interest, and withdrawals are not taxed</td>
<td>Contributions, interest, and withdrawals are not taxed; health savings accounts are portable across jobs</td>
</tr>
<tr>
<td>Restrictions on use of savings</td>
<td>List of eligible health services (e.g., inpatient care in approved hospitals); withdrawals subject to a daily and annual cap; substantial user charges to promote individual responsibility</td>
<td>Depending on the design of the scheme, the funds can be used to cover inpatient care, outpatient care, or both; some schemes also allow patients to use funds to pay for preventive care, as well as deductibles for social health insurance</td>
<td>Contributions capped; usually limited to covering outpatient care or user charges for care covered by private insurance; benefit structures are poorly defined and deductibles vary depending on the procedure</td>
<td>Contributions capped; most insurers provide a list of preferred providers that are accompanied by lower user charges; to support the use of preventive care, most plans exclude selected services (e.g. immunisations and diagnostic colonoscopies) from the deductibles</td>
</tr>
</tbody>
</table>

* This information relates to health savings accounts (HSAs)

**Source:** Adapted from Cylus and Thomson (2012).

**How well do MSAs meet their stated goals?**

This section reviews evidence on the effects of MSAs on efficiency, equity, and financial protection. These dimensions have been the focus of the empirical studies of MSAs to date. Two authors (O.J.W. and W.Y.) independently searched Cochrane, EconLit, MEDLINE, Scopus, and ISI Web of Science databases for peer-reviewed, empirical studies written in Chinese or English that looked at the association between MSAs and one or more of these three outcomes (i.e. efficiency, equity, and financial protection).

We searched titles and abstracts using the terms “consumer-directed health care”, “health savings account”, “medical savings account”, and the plural forms of these terms; we considered all literature published up until September 24, 2015, when the search was conducted. After removing duplicates and articles with no abstracts, both authors separately screened the abstracts/titles and reviewed the full texts of potentially relevant articles.
Disagreements over article inclusions were resolved through discussions between the two authors.

We also hand searched the reference lists of selected articles and one author (W.Y.) searched the China National Knowledge Infrastructure database using the term “medical savings account” (in Chinese). We identified other relevant peer-reviewed and grey literature from Google searches. Most of the available empirical evidence comes from the USA; we included studies of both HSAs and HRAs.

**Efficiency**

It is suggested that MSAs, like user charges, can enhance efficiency and, potentially, control health-care costs by reducing the use of low-value treatments. Analyses of selected employer-sponsored plans in the USA, however, have suggested that HSAs discourage the use of both low- and high-value treatments (Buntin et al. 2011; Dixon, Greene, and Hibbard 2008; Parente, Feldman, and Chen 2008; Hardie et al. 2010; Charlton et al. 2011). One study (Greene et al. 2008) observed that enrolment in consumer-directed health plans (CDHPs) did not greatly influence the use of generic medicines. Instead, enrollees in high-deductible CDHPs were two to three times more likely to discontinue pharmacologic treatment in two of five drug classes — anti-hypertensive and lipid-lowering medicines — than were enrollees with other types of coverage (Greene et al. 2008). Another study showed that enrollment in CDHPs with HSAs was associated with reduced adherence to medicines among patients with four out of five selected chronic conditions (Fronstin, Sepúlveda, and Roebuck 2013a).

Researchers have generally concluded that individuals who switch from traditional insurance plans to CDHPs tend to spend less on health care during the first one to three years after the switch compared to those who stay in traditional plans (Parente, Feldman, and Christianson 2004a; Lo Sasso, Shah, and Frogner 2010; Buntin et al. 2011; Charlton et al. 2011). This effect appears to be more pronounced for those who enrol in CDHPs with higher deductibles (Haviland et al. 2011). For example, an analysis of spending patterns over three years among 76,310 employees at small and midsized firms — 22,587 of whom enrolled in HSAs during that time — found that HSA enrollees spent, on average, between 5% and 7% less per year in total than non-HSA enrollees, controlling for confounders; much of the observed reduction in overall spending occurred during the first year of enrolment (Lo Sasso, Shah, and Frogner 2010). Another study showed that, on average, CDHP enrollees spent less overall over three years of follow-up than did enrollees in a preferred provider organisation (PPO), controlling for enrollee characteristics; CDHP enrollees, however, spent more than enrollees in a health maintenance organisation (HMO). The authors noted that these results were “not consistent across different types of medical expenditures, and there [were] differences by employer versus employee payment” (Parente, Feldman, and Christianson 2004a).

Yet, if MSAs deter the use of effective, high-value treatment where the benefits might not be immediate or obvious to patients (e.g. preventive care like cancer screening), this could raise health expenditure over time. One study observed that enrollees in a CDHP had both fewer prescriptions filled (0.26 per enrollee per year) and fewer office visits to physicians (0.85 per enrollee per year) after four years than did enrollees in a PPO, but the former group
also had slightly more emergency department visits after four years (0.018 per enrollee per year) (Fronstin, Sepulveda, and Roebuck 2013b). Another study similarly found that enrollees in a CDHP had, on average, fewer physician visits and fewer prescriptions filled than did enrollees in a PPO or a HMO during the study period; CDHP enrollees also routinely paid less out-of-pocket than did enrollees in the PPO (Parente, Feldman, and Christianson 2004a). Meanwhile, the CDHP cohort had a larger growth in hospital costs and admission rates between 2000 and 2002 than did enrollees in either the PPO or the HMO, with a sharp rise in hospital expenditure in the third year of follow-up among CDHP enrollees. The authors suggested that enrolment in a CDHP might have made the patients more price conscious and led them to forego care until they fell ill and needed to be hospitalised. However, the authors acknowledged it was not possible to attribute causality based on the study data (Parente, Feldman, and Christianson 2004a).

Such findings are in line with evidence from the RAND Health Insurance Experiment, which suggested that most patients are unable to distinguish consistently between high- and low-value treatments (Newhouse 1993). Not all US studies, however, have found that enrolment in CDHPs reduces the use of preventive care, probably because such care is often exempt from out-of-pocket payments (Rowe et al. 2008; Wilson et al. 2008; Cress and Zimmer 2011). Others have also found that educating HSA enrollees about the possible savings from choosing cheaper generic drugs instead of more expensive brand-name drugs is associated with greater use of the former (Sedjo and Cox 2009). Beyond such measures, however, it is unclear whether MSA plans can be designed in ways that consistently discourage the use of low-value care and not high-value care.

Another issue is that once individuals with an accompanying insurance plan have met the deductible, additional health care is usually covered at no extra charge by the insurer. Thus, even if MSAs discourage the use of low-cost, low-value health care, they are less likely to influence the use of costly health care over which these enrollees have less control (Monheit 2003; Stanton and Rutherford 2006).

MSAs are also unlikely to have a significant effect on health-care costs where they are voluntary, because low-income individuals and families, who account for a disproportionate share of health spending, have been shown to be less likely to enrol and/or contribute to their accounts (Parente, Feldman, and Christianson 2004a, 2004b; Minicozzi 2006; Chen, Lo Sasso, and Nandam 2013; Helmchen et al. 2015). Several studies have suggested that MSAs and CDHPs tend to attract healthier, lower-risk, younger, higher-income, and/or better-educated patients (Fowles et al. 2004; Lo Sasso et al. 2004; Tollen, Ross, and Poor 2004; Greene et al. 2006; Lo Sasso, Shah, and Frogoner 2010; Charlton et al. 2011), although not all analyses show that MSA enrollees are, on average, younger or healthier than non-MSA enrollees (Parente, Feldman, and Christianson 2004b; Minicozzi 2006). The demographics and health status of MSA enrollees are likely to depend in part on plan design and the incentives offered to enrollees by individual MSA providers.

Proponents of MSAs claim that they enhance consumer choice and encourage price competition if rational and informed consumers actively search for the cheapest care, assuming constant quality (i.e. active purchasing). In one study, enrollees in low-deductible CDHPs reported being more likely than enrollees in other plans to start using health-care information when seeking care, such as looking at drug costs from the previous year and
comparing quality information from different hospitals (Dixon, Greene, and Hibbard 2008). However, an interview-based study showed that only around half of the 458 adult interviewees — all of whom had recently enrolled in a CDHP with a deductible — were aware they had a deductible, while less than 7% knew which medical services were subject to or exempt from the deductible (Reed et al. 2009). Low awareness of such information is likely to impede MSA enrollees from engaging in active purchasing. One analysis also suggested that a large proportion of primary-care clinicians were not prepared, at the time of the study, to provide information to patients enrolled in HSAs about the costs of various medical services, including radiologic tests (54% of sampled clinicians reported being “ready” or “very ready”; 95% CI: 50-59%), specialist visits (38%; 95% CI: 33-42%), and hospitalisations (33%; 95% CI: 29-37%) (Mallya, Pollack, and Polsky 2008); more than two-thirds of the 528 respondents, however, felt ready to give advice to patients about the costs of laboratory tests, office visits, and medications.

Several articles have highlighted how difficult it is for patients to obtain price and quality information about health-care services in the USA (Reinhardt 2006; Muhlestein, Wilks, and Richter 2013), while interviews with health policy experts in South Africa found little price competition after the introduction of MSAs (Jost 2005). In South Africa, MSAs have instead shifted the focus of private insurers away from the active purchasing of more efficient, better-quality health care and towards risk selection and shifting costs onto policy holders to keep premiums low (McLeod and McIntyre 2008). In China, where a large proportion of health care is financed through out-of-pocket payments, it is common for doctors to ask patients during consultations whether they have funds available in their MSAs. This may lead some doctors to over-prescribe medicines and diagnostic tests to those with large surpluses in their accounts (Xue and Zhao 2007; Sheng and Hou 2011). Overall, more research is needed to determine whether it is feasible for institutions to collect and disseminate easy-to-understand price and quality data to patients in countries where MSAs are available. It would also be important to see whether patients could use such information effectively when purchasing health care.

Equity and financial protection

MSAs allow enrollees to spread the financial risk of ill health over time. They do not, however, ensure that people will have enough savings to pay for large, unexpected health-care bills, nor do they foster social solidarity (Jost 2007). In 2011, Medisave withdrawals and Medishield claims only accounted for about 5.5% and 2.1% of national health expenditure in Singapore, respectively (Singapore Ministry of Health 2013), with most health care paid for out-of-pocket. One study suggested that HSA enrollees in the USA who paid for their own accounts — with no employer contributions — were significantly more likely to report financial burdens than enrollees with only employer contributions (17.3% vs. 11.9%, p<0.05) (Reed et al. 2012).

In Singapore and China, the use of earned income to finance MSAs discriminates against retired, unemployed, disabled, and chronically ill people (Jost 2007). Meanwhile, a US study found that employees with chronic illnesses were more likely than other employees to deplete their HSA savings and to spend more on their deductibles (Parente, Christianson, and
Feldman 2007). Another analysis observed that enrolment in CDHPs was associated with a similar reduction in beneficial care among both vulnerable and non-vulnerable patient groups (Haviland et al. 2011). The authors posited that this might impact the health of low-income and chronically ill patients more than the health of non-vulnerable groups (Haviland et al. 2011).

Yip and Hsiao (2009) modelled the financial protection offered by first-dollar coverage plans and MSAs in rural Chinese regions based on household data. They determined that first-dollar plans were more likely to limit impoverishment due to medical expenses than MSAs coupled with high-deductible catastrophic coverage: the empirical model suggested that first-dollar plans would lower the poverty headcount by 6.1-6.8%, whereas joint MSAs/catastrophic insurance would lower the headcount by 3.5-3.9%. These calculations were based on a poverty line of USD 1.08 per person per day. The authors attributed this finding to the fact that MSA funds could not be spent on outpatient care, which was the main source of impoverishment for chronically ill people in the study regions. Liu and colleagues (2002) showed that the introduction of MSAs as part of employee health insurance in Zhenjiang, China, increased the use of outpatient health care among lower socioeconomic groups, although Yi and colleagues (2005) concluded that the Zhenjiang pilot model of health care financing was regressive. Data from the first year of the Jiujiang and Zhenjiang pilot studies suggested the reform shifted the financial burden from the healthy to the sick (Yip and Hsiao 1997). Those patients who exhausted the funds in their MSAs had to pay a deductible corresponding to 5% of their wages before insurance would begin to cover additional costs (Yip and Hsiao 1997). Pei (2008), Liu and Chen (2013), and Xia (2014) have all found that, because of the lack of risk pooling across individuals, Chinese patients with substantial health needs tend to deplete their MSAs, while young and healthy patients tend to keep large, unused surpluses in their accounts.

Tax exemptions and subsidies for MSAs in the USA and Singapore often benefit wealthier people disproportionately, especially when provided at the marginal rate of taxation so that individuals in higher tax brackets receive greater tax relief. Even if tax exemptions were provided at a standard rate, they would not benefit those who do not pay taxes, including unemployed people, non-working dependants, and individuals with earnings below the tax threshold (Glied and Remler 2005; Hoffman and Tolbert 2006; Minicozzi 2006).

Furthermore, HSAs attract a triple tax benefit in the USA: the contributions are tax-deductible, the earned interest is tax-free, and the withdrawals to pay for approved medical costs are tax-free. HSAs are marketed as effective savings vehicles to help people pay for health-care costs at older ages, as long as the savings are not used until retirement (Fronstin 2014); after age 65, HSA funds can be used to pay for non-medical expenses, without penalty, although ordinary taxes still apply. Such savings, however, would be more likely to benefit those individuals who are wealthy or healthy enough not to need the savings to cover out-of-pocket costs, including insurance premiums, before retirement. For example, one study estimated that a 55-year old couple setting up an HSA in 2008 would need to accumulate between USD 511,000 and USD 1 million by the age of 65 to have a 90% chance of having enough savings to cover these expenses in retirement, assuming premiums and other out-of-pocket costs do not rise faster than adjustments for inflation (Fronstin 2014).
Discussion

Country experiences with MSAs indicate the schemes have generally been inefficient and inequitable and have not provided adequate financial protection. The impact of the schemes on long-term health-care costs is unclear. The lack of interpersonal risk pooling in MSAs is a key limitation.

In China, the mismatch between MSA funds and need for health care led to a total MSA surplus of RMB 323 billion in 2014 (USD 50.5 billion based on the average exchange rate for that year), which was equal to the combined value of all social health insurance premiums (Xinhua News 2015). Some Chinese cities are experimenting with ways of making better use of MSA funds. In 2009, Zhenjiang City separated MSAs into two accounts. The main account can be used to pay for most types of care, including outpatient, inpatient, preventive, and long-term care; previously, it could only be used for outpatient care. All funds above RMB 3000 (USD 469) are saved in the secondary account, which can also be used to pay for the health care of family members (Xinhua News 2009). Since 2009, the Zhenjiang model has been adopted by a growing number of cities in China. In Chengdu City, for example, MSA participants can now use funds to pay for private health insurance premiums (Sichuan News 2015). Other cities, including Dalian, Shanghai, Shenyang, and Zhongshan, are piloting similar initiatives (Xinhua News 2015).

Yet, MSAs continue to be suggested as appropriate financing options in other countries, often by policymakers in finance ministries (Thomson et al. 2010). This may be because savings are so commonly used to finance pensions, and people seem to extrapolate from pensions to health. However, unlike the more predictable need for income replacement during retirement, ill health is characterised by a high degree of uncertainty, which means that individual savings alone cannot provide adequate financial protection for everyone faced with health–care expenses. It is also possible that the lobbying activities of stakeholders help bring MSAs to the forefront of political discussions. Banks and other companies offering financial services may have strong motives to encourage MSAs given the fees involved, while other individuals and groups may be ideologically driven to endorse individual accounts instead of options with mandatory risk pooling across individuals.

Some of the weaknesses of MSAs could be addressed by coupling MSAs with supply-side measures, like rewarding low-cost providers to correct price competition failures. If MSAs are to be adopted, it will also be important to foster an economic and regulatory environment that is conducive to market-oriented plans. Prerequisites for the viability and sustainability of MSAs include a high income per capita, a national culture of saving and personal responsibility for health, and a well-functioning and transparent regulatory environment, both in the health sector and in the financial services sector (Nichols, Prescott, and Phua 1997; Chia 2005).

Finally, this review has shown how MSAs are often coupled with high-deductible plans, both of which can take a variety of forms. It is not possible, with the evidence available, to draw firm conclusions about whether MSAs can ameliorate the problems associated with high-deductible plans. This is an area where more research is needed, although findings may be difficult to interpret given differences in context, such as the presence of other safety nets, as in Singapore. It is likely, however, that systems with greater complexity, where patients
draw on multiple plans, will leave more people to fall through the net. This is supported by findings cited earlier that indicate a social gradient in MSA take up and that show how few people fully understand the deductibles associated with plans in which they are already enrolled.

Despite the recent fervour over MSAs, the case that so-called consumer-directed solutions achieve their objectives remains unproven.

Acknowledgments

No sources of funding were used to prepare this manuscript. The authors have no conflicts of interest that are relevant to the content of this article.

References


